Nutex Health Inc. NUTX R2K
Healthcare · Medical Care Facilities · United States
Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.
READ MORE ›$129.11
-23.03% 1Y
Market & Price
Market Cap
$888.45M
Current Price
$129.11
High / Low (52W)
$190.49 / $80.92
Beta
2.07
Valuation
Stock P/E
9.44
Industry PE
23.65
Forward P/E
6.35
PEG Ratio
-
Book Value
$49.81
Price to Book
2.59
P/S
1.01
EV/EBITDA
2.72
Dividend Yield
-
Profitability & Returns
ROCE
35.10%
ROE
53.65%
ROA
28.59%
Profit Margin
10.95%
Op Margin
37.54%
EPS (Latest Qtr)
$6.52
EPS (TTM)
$13.67
Balance Sheet & Liquidity
Debt/Equity
0.79
Quick Ratio
3.00
Current Ratio
3.14
Debt
$349.09M
Total Assets
$918.52M
Current Assets
$538.81M
Working Capital
$380.90M
Ownership
Promoter Holding
29.02%
Chg in Prom Hold
-
FII / Inst Holding
42.59%
Chg in FII Hold
0.02%
Financial Snapshot
Enterprise Value
$1.13B
Total Revenue (TTM)
$879.95M
EBITDA
$414.16M
Free Cash Flow
$168.75M
Operating Cash Flow
$272.68M
Shares Outstanding
6.88M
Gross Margin
50.58%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
58.62%
Profit 5Y
38.89%
Revenue (YoY)
2.20%
Earnings (YoY)
95.90%
PROS
- Strong return on equity of 53.6%.
- Healthy ROCE of 35.1%.
- Compounding revenue at 58.6% over 5 years.
- Profit CAGR of 38.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 32.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NUTX Nutex Health Inc. R2K | 129.11 | 9.44 | $888.45M | - | 35.10% | 53.65% | 58.62% | 38.89% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.00M | - | - | - | - | - | - | - | - | - | 211.79M | 243.99M | 267.80M | 151.68M | 216.49M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 93.45M | 119.06M | 112.92M | 105.54M | 124.75M |
| Gross Profit | 186.72K | 153.95K | 164.72K | 180.32K | 186.34K | 400.56K | 0 | 0 | 4.17K | -9.84K | 11.06K | -3.74K | -4.17K | 14.75K | 43.68K | -1.79K | 111.26K | 266.50K | 113.73K | 139.14K | 426.87K | 29.14M | 76.01M | 35.82M | 6.64M | -23.71M | 530.32K | 4.85M | 9.65M | 7.07M | 13.21M | 10.16M | 22.56M | - | - | 118.34M | 124.92M | 154.88M | 46.14M | 91.73M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.68M | 91.25M | 24.51M | 15.22M | 10.46M |
| Operating Income | -201.25K | -184.34K | -143.19K | -86.80K | -121.83K | -161.94K | -64.51K | -75.70K | -163.21K | -1.25M | -711.94K | -411.97K | -489.01K | -367.01K | -925.91K | -374.71K | -906.13K | -939.91K | 645.56K | 1.78M | -4.15M | 27.60M | 74.46M | 29.24M | -1.38M | -428.68M | -5.78M | -4.45M | -362.54K | -821.23K | -26.14M | 1.45M | 5.30M | - | - | 80.66M | 33.68M | 130.37M | 30.92M | 81.27M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 82.43M | 34.66M | 134.39M | 36.06M | 86.73M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.12M | 5.68M | 5.45M | 4.98M | 4.68M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.22M | 23.73M | 123.94M | 25.89M | 76.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.41M | 7.59M | 27.14M | 9.29M | 13.80M |
| Net Income | -75.27K | -185.76K | -144.90K | -51.65K | -74.85K | -238.87K | -96.05K | 216.67K | -242.07K | -1.65M | 6.33M | -610.03K | -726.25K | -608.52K | -968.16K | -570.37K | -857.63K | -1.12M | 227.31K | 1.76M | -4.48M | 29.68M | 74.49M | 21.44M | -19.28M | -412.19M | -14.75M | -5.15M | -3.48M | -5.54M | -31.62M | -364.00K | -364.00K | - | - | 21.22M | -17.70M | 55.44M | 11.83M | 46.81M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.05 | 0.09 | 0.04 | -0.03 | -0.62 | -0.02 | -0.12 | -0.79 | -1.25 | -7.47 | -0.08 | -0.07 | - | 11.12 | 3.33 | -2.95 | 7.76 | - | 6.52 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 181.25K | - | 107.76K | 114.88K | 314.25K | 73.83K | 76.72K | 59.63K | 72.27K | 73.75K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 1.37M | 1.37M | 274.03M | 331.53M | 219.29M | 247.65M | 479.95M | 875.26M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 203.87M | 212.87M | 283.69M | 430.98M |
| Gross Profit | 483.19K | 1.02M | 810.38K | 965.17K | 603.28K | 466.63K | 0 | -7.32K | 859.36K | 535.98K | 157.61M | 179.28M | 15.42M | 34.77M | 196.26M | 444.28M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 20.00M | 36.28M | 58.48M | 168.66M |
| Operating Income | -1.35M | -844.58K | -1.57M | -727.38K | -723.43K | -532.99K | -448.60K | -5.69M | -840.40K | -6.90M | 153.17M | 170.26M | -4.58M | -1.51M | 137.78M | 275.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -394.03M | -14.58M | 148.73M | 287.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 12.49M | 16.32M | 19.93M | 22.23M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -419.65M | -48.49M | 109.83M | 244.78M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 13.09M | -5.07M | 15.02M | 64.42M |
| Net Income | 158.14K | -383.39K | -1.62M | 250.49K | -684.34K | 83.81K | -7.43M | 582.06K | -950.13K | -7.12M | 105.97M | 132.59M | -424.78M | -45.79M | 52.10M | 70.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | 0.18 | 0.22 | -100.50 | -10.50 | 9.71 | 10.48 |
| R&D Expense | - | - | - | - | - | - | - | - | 545.22K | 768.10K | 557.26K | 285.88K | - | - | - | - |
Compounded Sales Growth
| 5 Years: | 58.62% |
| 1 Year: | 2.20% |
Compounded Profit Growth
| 5 Years: | 38.89% |
| 1 Year: | 95.90% |
Stock Price Performance
| 1 Year: | -23.03% |
| 6 Months: | +8.30% |
| 3 Months: | +16.88% |
| 1 Month: | +15.26% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 2.34M | 1.89M | 745.92K | 1.07M | 280.79K | 7.64M | 510.83K | 3.33M | 449.43K | 6.69M | 169.86K | - | 431.75M | 398.25M | 655.32M | 918.52M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 97.97M | 90.85M | 292.48M | 538.81M |
| Cash & Equivalents | 465.55K | 224.80K | 104.72K | 26.87K | 126.83K | 122.29K | 10.52K | 9.45K | 119.27K | 1.07M | 26.93K | - | 34.26M | 22.00M | 40.64M | 185.57M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 3.53M | 3.39M | 2.85M | 2.87M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 58.32M | 62.78M | 236.05M | 325.42M |
| Total Liabilities | - | - | - | - | 285.28K | 6.08M | 6.38M | - | 1.95M | 4.83M | 1.30M | - | 311.42M | 319.14M | 466.79M | 495.09M |
| Current Liabilities | 351.62K | 288.58K | 440.22K | 515.15K | 285.28K | 6.08M | 6.38M | 959.78K | 1.04M | 4.61M | 1.15M | - | 54.86M | 58.31M | 154.22M | 157.91M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 23.05M | 26.31M | 22.47M | 29.17M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 267.20M | 275.76M | 340.30M | 351.39M |
| Total Equity | - | - | - | - | - | 1.56M | -5.87M | -997.22K | -1.50M | 1.86M | -1.13M | - | 95.86M | 61.45M | 132.44M | 329.45M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 4.33M | 4.51M | 5.51M | 7.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.64M | -659.14K | -518.69K | -183.15K | 159.20K | 44.91K | -274.22K | -714.62K | -480.05K | -4.04M | 86.67M | - | 50.61M | 1.26M | 23.15M | 248.12M |
| Investing Cash Flow | 1.22M | 413.39K | 417.74K | 1.80K | -4.74K | 1.83K | -9.99K | 2.05K | -116.96K | -748.20K | -61.19M | - | -4.34M | -11.24M | -5.61M | -5.24M |
| Financing Cash Flow | 22.89K | - | -19.13K | 103.50K | -54.50K | -51.28K | 172.44K | 711.50K | 704.57K | 5.73M | -7.97M | - | -48.13M | -2.27M | 1.09M | -97.95M |
| Capital Expenditure | 5.69K | 19.39K | 8.06K | - | 2.03K | 1.80K | - | - | -0 | -84.00K | -61.19M | - | -14.63M | -9.50M | -2.30M | -2.53M |
| Free Cash Flow | -1.63M | -639.75K | -510.63K | - | 161.23K | 46.70K | - | - | -480.05K | -4.12M | 25.48M | - | 35.97M | -8.24M | 20.85M | 245.60M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -1.86M | -12.25M | 18.64M | 144.93M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 5.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 62.9% | 39.2% | 57.5% | 54.1% | 7.0% | 14.0% | 40.9% | 50.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | -61.5% | -504.8% | 55.9% | 51.4% | -2.1% | -0.6% | 28.7% | 31.5% |
| Net Margin % | - | - | - | - | - | - | - | - | -69.5% | -520.8% | 38.7% | 40.0% | -193.7% | -18.5% | 10.9% | 8.1% |
| ROE % | - | - | - | - | - | 5.4% | 126.6% | -58.4% | 63.5% | -382.9% | -9,346.5% | - | -443.1% | -74.5% | 39.3% | 21.5% |
| ROCE % | -67.8% | -52.7% | -514.6% | -130.8% | 16,108.5% | -34.1% | 7.6% | -240.3% | 141.3% | -331.3% | -15,569.7% | - | -1.2% | -0.4% | 27.5% | 36.2% |
Shareholding Pattern
Insiders
29.02%
Institutions
42.59%
Public Float
60.00%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.51% | 379.36K | $48.98M |
| 2 | Pertento Partners LLP | 5.43% | 373.97K | $48.28M |
| 3 | Vanguard Capital Management LLC | 3.18% | 219.13K | $28.29M |
| 4 | American Century Companies Inc | 2.96% | 203.45K | $26.27M |
| 5 | Topline Capital Management, LLC | 2.58% | 177.80K | $22.96M |
| 6 | State Street Corporation | 1.79% | 123.18K | $15.90M |
| 7 | Geode Capital Management, LLC | 1.77% | 122.11K | $15.77M |
| 8 | Millennium Management Llc | 1.30% | 89.57K | $11.56M |
| 9 | UBS Group AG | 1.01% | 69.57K | $8.98M |
| 10 | Winmill & Co. Inc | 0.95% | 65.35K | $8.44M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NUTX
No recent headlines available.